CHIMERA BIOENGINEERING INC has a total of 34 patent applications. It decreased the IP activity by 90.0%. Its first patent ever was published in 2016. It filed its patents most often in United States, EPO (European Patent Office) and WIPO (World Intellectual Property Organization). Its main competitors in its focus markets biotechnology, pharmaceuticals and foods and drinks are SHENZHEN IN VIVO BIOMEDICINE TECH LIMITED COMPANY, CHEMOTHERAPEUTISCHES FORSCHUNGSINSTITUT GEORG SPEYER HAUS and MOGAM INST BIOMEDICAL RES.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 19 | |
#2 | EPO (European Patent Office) | 6 | |
#3 | WIPO (World Intellectual Property Organization) | 6 | |
#4 | China | 3 |
# | Industry | |
---|---|---|
#1 | Biotechnology | |
#2 | Pharmaceuticals | |
#3 | Foods and drinks | |
#4 | Measurement | |
#5 | Organic fine chemistry |
# | Technology | |
---|---|---|
#1 | Microorganisms | |
#2 | Therapeutic chemical compounds | |
#3 | Peptides | |
#4 | Medical preparations | |
#5 | Enzymes | |
#6 | Measuring microorganism processes | |
#7 | Combinatorial chemistry | |
#8 | Analysing materials |
# | Name | Total Patents |
---|---|---|
#1 | Wang Benjamin | 34 |
#2 | Zeiner Gusti | 34 |
#3 | Mcnally Krista | 6 |
#4 | Dylla Scott | 2 |
Publication | Filing date | Title |
---|---|---|
US2021046117A1 | Combination Therapy with Gold Controlled Transgenes | |
WO2019160815A1 | Coordinating gene expression using rna destabilizing elements | |
US2018127776A1 | Ligand Matched Transcription Control, Control Devices, and Solute Carriers | |
EP3506916A1 | Gold optimized car t-cells | |
US2017336393A1 | Methods for making novel antigen binding domains | |
US2017157176A1 | Smart CAR Devices and DE CAR Polypeptides for Treating Disease and Methods for Enhancing Immune Responses | |
WO2016149254A1 | Smart car devices, de car polypeptides, side cars and uses thereof |